These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 31164374)

  • 1. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family matters: How MYC family oncogenes impact small cell lung cancer.
    Brägelmann J; Böhm S; Guthrie MR; Mollaoglu G; Oliver TG; Sos ML
    Cell Cycle; 2017 Aug; 16(16):1489-1498. PubMed ID: 28737478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
    Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
    Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
    Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells.
    Munksgaard Thorén M; Vaapil M; Staaf J; Planck M; Johansson ME; Mohlin S; Påhlman S
    Oncotarget; 2017 Jul; 8(30):48983-48995. PubMed ID: 28430666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
    Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D
    Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
    Huang F; Huffman KE; Wang Z; Wang X; Li K; Cai F; Yang C; Cai L; Shih TS; Zacharias LG; Chung A; Yang Q; Chalishazar MD; Ireland AS; Stewart CA; Cargill K; Girard L; Liu Y; Ni M; Xu J; Wu X; Zhu H; Drapkin B; Byers LA; Oliver TG; Gazdar AF; Minna JD; DeBerardinis RJ
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33079728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
    Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
    BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.
    Suda K; Rozeboom L; Yu H; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    PLoS One; 2017; 12(2):e0172209. PubMed ID: 28192473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
    Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
    Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.
    Ciampricotti M; Karakousi T; Richards AL; Quintanal-Villalonga À; Karatza A; Caeser R; Costa EA; Allaj V; Manoj P; Spainhower KB; Kombak FE; Sanchez-Rivera FJ; Jaspers JE; Zavitsanou AM; Maddalo D; Ventura A; Rideout WM; Akama-Garren EH; Jacks T; Donoghue MTA; Sen T; Oliver TG; Poirier JT; Papagiannakopoulos T; Rudin CM
    Cancer Discov; 2021 Dec; 11(12):3214-3229. PubMed ID: 34344693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
    Kawabata S; Connis N; Gills JJ; Hann CL; Dennis PA
    Anticancer Res; 2021 Jan; 41(1):91-99. PubMed ID: 33419802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
    Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
    J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.
    Krencz I; Sztankovics D; Danko T; Sebestyen A; Khoor A
    Cancer Metastasis Rev; 2021 Dec; 40(4):1141-1157. PubMed ID: 34958428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer.
    Yu J; Wang S; Zhao W; Duan J; Wang Z; Chen H; Tian Y; Wang D; Zhao J; An T; Bai H; Wu M; Wang J
    Clin Cancer Res; 2018 May; 24(9):2148-2158. PubMed ID: 29437792
    [No Abstract]   [Full Text] [Related]  

  • 18. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs.
    Pal Choudhuri S; Girard L; Lim JYS; Wise JF; Freitas B; Yang D; Wong E; Hamilton S; Chien VD; Kim YJ; Gilbreath C; Zhong J; Phat S; Myers DT; Christensen CL; Mazloom-Farsibaf H; Stanzione M; Wong KK; Hung YP; Farago AF; Meador CB; Dyson NJ; Lawrence MS; Wu S; Drapkin BJ
    Cancer Discov; 2024 May; 14(5):804-827. PubMed ID: 38386926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
    Prudner BC; Rathore R; Robinson AM; Godec A; Chang SF; Hawkins WG; Hirbe AC; Van Tine BA
    Clin Cancer Res; 2019 Aug; 25(16):5122-5134. PubMed ID: 31113844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.